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LETTER TO THE EDITORPrimary CNS Lymphoma—
Radiation-Free Salvage
Therapy by Second Autologous
Stem Cell Transplantation
Primary central nervous system lymphoma
(PCNSL) is a rare aggressive extranodal non-Hodgkin
lymphoma mostly of B-cell origin confined to the
CNS compartment. High-dose methotrexate (HD-
MTX) plus cytarabine (AraC) is considered as standard
first-line therapy, but despite high response rates, the
majority of patients still relapse [1,2], and because
there is no consensus treatment for relapse, reported
strategies vary strongly. High-dose chemotherapy plus
autologous stem cell transplantation (HDC-ASCT)
has been shown tobe feasible and effective as initial ther-
apy [3,4].Were herein report the treatment strategies of
3 immuncompetent patients with recurrent PCNSL
after first-line HDC-ASCT. Systemic lymphoma man-
ifestation at time of diagnosis and relapse was ruled out
by CT total body scans, bone marrow biopsy aspirate,
and positron emission tomography (PET). Staging was
carried out by contrast-enhanced magnetic resonance
imaging (MRI) scans. Epstein-Barr association was
ruled out a time of diagnosis. Our patients gave written
informed consent for institutional-initiated research
studies.PATIENT 1
A27-year-oldmanwas diagnosedwithmultifocal an-
aplastic large-cell T cell lymphoma (Figure 1A). First-
line therapy: 4 applications of HD-MTX and 2 cycles
of AraC/thiotepa (TT) followed by ASCT (CD341
count 12.38  106/kg) after conditioning chemotherapy
with BCNU and TT [3]. One month after therapy com-
plete remission (CR) was confirmed (Figure 1B). After 2
years, MRI revealed multifocal relapse at the spinal cord
expressed by weakness and pain in the right leg
(Figure 1C andD). Salvage treatment: 2 cycles consisting
ofHD-MTX (3.5mg/m2 over 4 hours, day 1), AraC (2
2 g/m2/day, days 2-3), and TT (30 mg/m2, day 4). After
the second cycle partial remission (PR) of the spinal le-
sions and ongoing CR in the brain were confirmed. Be-
cause of the very good clinical condition we decided for
a second HDC-ASCT. Conditioning chemotherapy
consisted of busulfan (3.2 mg/kg/day over 3 hours, days
28 and27) andTT (2 5mg/kg/day, days25 and24).
After a second ASCT (CD341 count 10.87  106/kg)the patient obtained ongoing CR for now more than 12
months (Figure 1E).PATIENT 2
A 41-year-old man was diagnosed with a single
PCNSL; type diffuse large cell B-cell lymphoma
(DLCBL). First-line therapy: HD-MTX followed by
AraC and TT as induction therapy. For consolidation
he received HDC-ASCT (CD341 count 9.68  106/
kg) [4]. The patient refused whole-brain radiotherapy
(WBRT) after ASCT, which was part of the protocol.
One month after ASCT he was in ongoing CR for 7
years. At relapse, staging demonstrated multifocal le-
sions. Salvage treatment: 4 cycles of rituximab (375
mg/m2, day 1), HD-MTX (4 g/m2 over 4 hours, day
0), AraC (2 g/m2/day, days 1-2), and TT (30 mg/m2,
day 3) as induction, leading to CR after the first cycle.
For consolidation, we decided for a second ASCT
(CD341 count 7.85  106/kg) after conditioning che-
motherapy with busulfan (2  3.2 mg/kg/day over 3
hours, days 28 and 27) and TT (2  5 mg/kg/day,
days 25 and 24). After 6 months an MRI showed
ongoing CR.PATIENT 3
A 47-year-old man was diagnosed with a single
PCNSL; type DLCBL. First-line therapy consisted of
6 cycles according to theBonn protocol, without intraven-
tricular chemotherapy leading toCR [5]. Three months
later, MRI revealed multifocal relapse. Salvage treat-
ment: 2 cycles of AraC and TT, followed by HDC-
ASCT consisting of BCNU and TT (CD341 count
not given). Staging revealed CR. Fifteen months after
successful salvage treatment, stagingdemonstratedasec-
ond relapse. A second salvage treatment consisted of 5
cycles rituximab andHD-MTX followed by 2 cycles rit-
uximab, AraC, and TT according to our center’s new
PCNSL protocol (trail number: NCT00647049).
Before the second ASCT, MRI revealed CRu. Condi-
tioning regimen consisted of rituximab (375 mg/m2,
day 29), busulfan (3.2 mg/kg/day over 3 hours, days
28 and 27) and TT (2  5 mg/kg/day, days 25 and
24), leading to CR (CD341 count 9.88  106/kg at
the second ASCT). More than 1.5 years afterward the
patient is still in ongoing CR.
All patients collected stem cells after the first
AraC/TT cycle. Patients 1 and 2 both had a second
sufficient harvest before the second ASCT after 1 stim-
ulation. Patient 3 used stem cells from the first harvest.281
Figure 1. (A) Right parietal lymphoma at time of diagnosis; (B) complete remission after the first HDC-ASCT; (C,D) spinal lymphoma relapse;
(E) complete remission after the second HDC-ASCT (A, B, D, E contrast-enhanced T1-weighted MRI; C, T2-weighted MRI).
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ASCT was unremarkable in all patients. Time of
leucopenia (\1000/mL) and thrombopenia requiring
substitution (\10,000/mL) lasted 8 days in all patients.
There were no severe infectious complications. Up to
now, all 3 patients are in an excellent clinical condition
without neurocognitive impairments.
Recurrence of PCNSL remains a substantial prob-
lem, but there is little consensus on second-line treat-
ments. WBRT has an important role in patients with
chemorefractory or relapsed disease [6]; however,
long-term survivors often suffer from neurocognitive
impairment [7]. HDC-ASCT in PCNSL has been in-
vestigated in single-arm prospective trials for first-line
and salvage treatment leading to high remission rates.
Treatment-related mortality (TRM) remains a main
concern, and severe neurotoxicity is observed particu-
larly in patients receiving HDC-ASCT plus WBRT,
or when WBRT was applied during prior therapy (re-
viewed by [8]). In our patients, time to relapse after the
first HDC-ASCT varied strongly from 15 months to 7
years. The first patient was diagnosed with anaplastic
large-cell T cell lymphoma. Whether this rare sub-
type has an unfavorable prognosis is unknown. Re-
garding time of relapse in this patient, it fits to the
range observed in PCNSL of B-cell origin. The sec-
ond patient shows a relapse after 7 years and belongs
to the rare cases in which relapse occurs after long-
term remission [1]. The third patient experienced 2
relapses. The first occurred 8 months after being
treated according to the modified Bonn protocol, whichled to impressive survival rates, but because the
intraventricular therapy was omitted, the following
study needed to be stopped because of early relapses
[5,9]. Concerning induction therapy, regimens
slightly differed: in the third patient, HD-MTX was
omitted because of the early onset of relapse 3 months
after MTX containing therapy. Concerning patients 2
and 3, rituximab became part of our protocols. In all
cases, we decided for busulfan instead of BCNU be-
fore the second ASCT, because of the potential cumu-
lative toxicity of BCNU. We also considered WBRT
as salvage or consolidation treatment; however, having
in mind the risk of leucoencephalopathy in these
young patients, WBRT was not applied, but this re-
mains a debatable issue. Granted, one also needs to
consider the risk for development of secondary MDS
in long-term after remobilization for second ASCT,
but because the induction treatment based on antime-
tabolites (MTX, AraC) with rather low stem cell toxic-
ity we assume a lower over all risk for MDS
development in the long term, but still, this has to be
awaited. Allogeneic SCT instead of second ASCT
might also be considered because a graft-versus-
lymphoma effect in the brain has been described, but
this is still controversial [10]. Although follow-up is
still short, this series demonstrates the feasibility and
high efficacy of a second HDC-ASCT in relapsed
PCNSL. Our patients were in excellent clinical condi-
tion; thus, this approach needs to be cautiously consid-
ered basing on tumor-related and patient-related
characteristics.
Biol Blood Marrow Transplant 17:281-283, 2011 283Letter to the EditorREFERENCES
1. Jahnke K, Thiel E, Martus P, et al. Relapse of primary central
nervous system lymphoma: clinical features, outcome and prog-
nostic factors. J Neurooncol. 2006;80:159-165.
2. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus
high-dose methotrexate versus high-dose methotrexate alone in
patients with primary CNS lymphoma: a randomised phase 2
trial. Lancet. 2009;374:1512-1520.
3. Illerhaus G, Muller F, Feuerhake F, Schafer AO, Ostertag C,
Finke J. High-dose chemotherapy and autologous stem-cell
transplantation without consolidating radiotherapy as first-line
treatment for primary lymphoma of the central nervous system.
Haematologica. 2008;93:147-148.
4. Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy
with autologous stem-cell transplantation and hyperfractionated
radiotherapy as first-line treatment of primary CNS lymphoma.
J Clin Oncol. 2006;24:3865-3870.
5. Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central
nervous system lymphoma: results of a pilot and phase II study of
systemic and intraventricular chemotherapy with deferred radio-
therapy. J Clin Oncol. 2003;21:4489-4495.
6. Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH,
Batchelor TT, Loeffler JS. Results of whole-brain radiation as
salvage of methotrexate failure for immunocompetent patients
with primary CNS lymphoma. J Clin Oncol. 2005;23:1507-1513.
7. Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neuro-
toxicity in primary central nervous system lymphoma. Arch Neu-
rol. 2005;62:1595-1600.
8. Ferreri AJ, Crocchiolo R, Assanelli A, Govi S, Reni M.
High-dose chemotherapy supported by autologous stem celltransplantation in patients with primary central nervous
system lymphoma: facts and opinions. Leuk Lymphoma.
2008;49:2042-2047.
9. Pels H, Juergens A, Glasmacher A, et al. Early relapses in
primary CNS lymphoma after response to polychemotherapy
without intraventricular treatment: results of a phase II study.
J Neurooncol. 2009;91:299-305.
10. Varadi G, Or R, Kapelushnik J, et al. Graft-versus-lymphoma
effect after allogeneic peripheral blood stem cell transplantation







1Department of Hematology and Oncology
2Department of Neuroradiology, UniversityMedical Centre Freiburg,
Freiburg, Germany
E-mail address: gerald.illerhaus@uniklinik-freiburg.de
Biol Blood Marrow Transplant 17: 281-283 (2011)
 2011 American Society for Blood and Marrow Transplantation
doi:10.1016/j.bbmt.2010.11.011
